Peptide LibraryCardiogen
Also known as: Heart bioregulator, AEDR
Cardiogen (also called Heart bioregulator or AEDR) is a khavinson bioregulator. Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 489.49 g/mol
- Half-life
- Not established (limited PK data; primarily research context)
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Cardiomyocytes (proposed)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 13
- Listed offers
- 15
- Median price per mg (peptide vials)
- $3.25/mg
- Typical $3.00–$3.55/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials12 vendors · median $3.25/mg
- Capsules1 vendor
Research summary
Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies3 reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Cardiogen profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Cardiogen dosage: no established human dose
Cardiogen has no established human dosage. It is described as the synthetic tetrapeptide Ala-Glu-Asp-Arg, and no human study of it is indexed in PubMed or registered on ClinicalTrials.gov. Its indexed work is in rats and in cell or tissue culture, from Russian research groups.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Cardiogen is a short synthetic peptide in the Khavinson series, sold as a heart bioregulator. Its indexed studies are a rat tumour study, rat heart tissue culture and human cell culture, mostly in Russian-language journals. None reports a dose given to a person, so nothing here establishes a human dose, route or interval.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — cardiogen and transplanted M-1 sarcoma in senescent rats (2009)Preclinical · Animal study | Senescent rats with transplanted M-1 sarcoma | Not stated in the indexed abstract (non-human); the authors report a dose-dependent effect | Injection (type not stated in the indexed abstract) | — | — | Slower tumour growth with more tumour-cell apoptosis and haemorrhagic necrosis | Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats. Bull Exp Biol Med. 2009. |
| Preclinical — heart-muscle tissue culture from young and old rats (2009)Preclinical · Tissue-culture study | Myocardial explants from 3- and 24-month-old rats | 10^-12 M in culture (not a dose given to an animal or a person) | In vitro, added to culture | — | — | More cell proliferation and lower p53 expression in explants from young and old rats | The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats. Adv Gerontol. 2009. |
| In vitro — ageing human prostate fibroblasts (2010)Preclinical · Cell-culture study | Cultured human prostate fibroblasts | Not stated in the indexed abstract; added to cell culture, not given to a person | In vitro, added to culture | — | — | Higher expression of CXCL12, WEDC1 and ghrelin in ageing cultures; another peptide (T-38) was the most active | Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging. Adv Gerontol. 2010. |
Where sources disagree
- Protocols of 5–20 mg daily circulate for cardiogen. No indexed human study or registered trial reports a dose, and no primary source for those figures could be identified.
- Most search results for "CardioGen" concern CardioGen-82, a rubidium-82 generator used for heart PET scans, and a Hungarian cardiomyopathy registry. Neither is related to the peptide.
- The heart-protection claims rest on tissue-culture work; no indexed study has measured a heart outcome in people given cardiogen.
Reconstitution
Common research vial sizes: 20 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 20 mg | 2 mL | 10 mg/mL | 100 mcg per 0.01 mL |
| 20 mg | 4 mL | 5 mg/mL | 50 mcg per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- Reconstitute with bacteriostatic water if lyophilized (research only)
- Injection Sites
- Abdomen (subQ)
- Concentration Example
- 10 mg vial reconstituted with 2 mL = 5 mg/mL
- Timing Notes
- Often administered in the morning
- Expected Onset
- Variable; gene expression changes proposed over weeks
How to reconstitute Cardiogen
- Check the vial size and diluent volume. The profile example for Cardiogen is: Reconstitute with bacteriostatic water if lyophilized (research only).
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 10 mg vial reconstituted with 2 mL = 5 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Sequence & molecular data
| Amino acid sequence | Ala-Glu-Asp-Arg (AEDR) |
|---|---|
| Molecular formula | C18H31N7O9 |
| Molecular weight | 489.49 g/mol |
| Half-life | Not established (limited PK data; primarily research context) |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis. The supporting literature is principally cell-culture and cytogenetic work from a single group, published largely in Russian-language journals, and has not been replicated in contemporary randomised controlled trials. No specific receptor or characterised signalling pathway has been demonstrated.
Origin
Synthetic short peptide bioregulator.
Targets
Studies
- [Peptidergic regulation of age-related alterations in the cardiovascular system.]
- Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats
- [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats]
- [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging]
Research statistics
12 PubMed publications · 25.0% human clinical research · 1 registered trial
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Cardiogen is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Cardiogen side effects
Cardiogen has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Not well characterized
Stacking
Common stacking partners
Combinations that include Cardiogen, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Cardiogen: frequently asked questions
What is Cardiogen?
Short peptide sold as a cardiac bioregulator in the Khavinson series. No FDA approval; evidence is historical Russian literature.
How does Cardiogen work?
Cardiogen is Ala-Glu-Asp-Arg, a synthetic tetrapeptide in the Khavinson series associated with cardiac tissue. As with the rest of that series the proposed mechanism is direct interaction of the short peptide with promoter regions of DNA in the nucleus, modulating transcription of genes relevant to the target tissue — here cardiomyocyte protein synthesis.
Is Cardiogen FDA approved?
No. Cardiogen is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Cardiogen?
Reported half-life for Cardiogen is Not established (limited PK data; primarily research context). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Cardiogen?
Cardiogen has the sequence Short peptide complex (exact proprietary sequences not publicly standardized). Its molecular formula is Varies (short peptide fraction complex).
What peptides are similar to Cardiogen?
Compounds most often compared with Cardiogen include Bonomarlot, Bronchogen, Cartalax and Cerluten. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- [Peptidergic regulation of age-related alterations in the cardiovascular system.] — Adv Gerontol, 2026External reference
- Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats — Bull Exp Biol Med, 2009External reference
- [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats] — Adv Gerontol, 2009External reference
- [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging] — Adv Gerontol, 2010External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Cardiogen profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Cardiogen research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →